JP2000239304A - Cell culture substrate - Google Patents
Cell culture substrateInfo
- Publication number
- JP2000239304A JP2000239304A JP11043286A JP4328699A JP2000239304A JP 2000239304 A JP2000239304 A JP 2000239304A JP 11043286 A JP11043286 A JP 11043286A JP 4328699 A JP4328699 A JP 4328699A JP 2000239304 A JP2000239304 A JP 2000239304A
- Authority
- JP
- Japan
- Prior art keywords
- hyaluronic acid
- cell culture
- culture substrate
- gel
- aqueous solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000758 substrate Substances 0.000 title claims abstract description 32
- 238000004113 cell culture Methods 0.000 title claims abstract description 29
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 123
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 122
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 122
- 239000007864 aqueous solution Substances 0.000 claims abstract description 24
- 230000007935 neutral effect Effects 0.000 claims abstract description 11
- 238000005903 acid hydrolysis reaction Methods 0.000 claims description 9
- 238000004090 dissolution Methods 0.000 claims description 3
- 239000000835 fiber Substances 0.000 claims description 2
- 241000694440 Colpidium aqueous Species 0.000 claims 1
- 239000000243 solution Substances 0.000 abstract description 11
- 239000000126 substance Substances 0.000 abstract description 11
- 239000003431 cross linking reagent Substances 0.000 abstract description 6
- 239000000463 material Substances 0.000 abstract description 6
- 238000012258 culturing Methods 0.000 abstract description 3
- 210000000056 organ Anatomy 0.000 abstract description 3
- 239000000499 gel Substances 0.000 description 46
- 238000007710 freezing Methods 0.000 description 17
- 230000008014 freezing Effects 0.000 description 17
- 238000010257 thawing Methods 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 11
- 210000003491 skin Anatomy 0.000 description 11
- 238000000034 method Methods 0.000 description 9
- 239000002253 acid Substances 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 239000002904 solvent Substances 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 210000004927 skin cell Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- -1 alkali metal salts Chemical class 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 241000194048 Streptococcus equi Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000005299 abrasion Methods 0.000 description 2
- 239000003929 acidic solution Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000010382 chemical cross-linking Methods 0.000 description 2
- 229940059329 chondroitin sulfate Drugs 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 238000000569 multi-angle light scattering Methods 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 229920000288 Keratan sulfate Polymers 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 241000194022 Streptococcus sp. Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
Landscapes
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
(57)【要約】
【課題】 なんら架橋剤等を使用することなく、安全性
及び生体適合性に優れ、各種細胞を培養用基材の内部及
び又は表面で培養することにより、人工皮膚等の人工臓
器の構築材料として利用できる他、細胞培養による有用
物質の生産にも利用できる細胞培養用基材を提供するこ
と。
【解決手段】 中性水溶液に難溶性であるヒアルロン酸
単独で形成されたゲルを含有する細胞培養用基材を構成
とする。(57) [Summary] [PROBLEMS] An artificial skin or the like by culturing various cells inside and / or on the surface of a culture substrate without using any crosslinking agent or the like, and having excellent safety and biocompatibility. Provided is a cell culture substrate that can be used as a material for constructing an artificial organ and also used for producing a useful substance by cell culture. SOLUTION: The cell culture substrate comprises a gel formed of hyaluronic acid alone which is hardly soluble in a neutral aqueous solution.
Description
【0001】[0001]
【発明の属する技術分野】本発明は、中性水溶液に難溶
性であるヒアルロン酸単独で形成されたゲルを含有する
細胞培養用基材に関する。TECHNICAL FIELD The present invention relates to a cell culture substrate containing a gel formed of hyaluronic acid alone which is hardly soluble in a neutral aqueous solution.
【0002】[0002]
【従来の技術】従来、火傷や擦過傷等による皮膚損傷の
治療には、損傷部位をカバーし、欠損した組織を補充す
るために、ヒト皮膚の移植、あるいは、凍結乾燥豚真皮
やキチンを用いた不織布などの創傷被覆材が用いられて
きた。しかし、皮膚移植は採取できる量が限られ、又、
創傷被覆材は損傷をカバーするだけで、皮膚の機能を代
替するものではない為、より効果的な治療法として、損
傷部位で皮膚細胞の増殖の場を提供する培養基材からな
る人工皮膚や、あらかじめ培養基材に皮膚細胞を培養し
た人工皮膚が研究されている。2. Description of the Related Art Conventionally, in the treatment of skin damage due to burns, abrasions, etc., human skin transplantation or freeze-dried swine dermis or chitin has been used to cover the injured site and replace defective tissue. Wound dressings such as nonwovens have been used. However, the amount of skin transplants that can be collected is limited,
Wound dressings only cover the damage and do not replace the function of the skin.Therefore, more effective treatments include artificial skin made of a culture substrate that provides a place for the growth of skin cells at the damaged site. Artificial skin in which skin cells are cultured in advance on a culture substrate has been studied.
【0003】このような人工皮膚に用いられる培養基材
の材料としては、高い生体適合性と生体吸収性に加え
て、損傷に応じて様々な形態が選べるものが望ましく、
コラーゲン、コンドロイチン硫酸、ヒアルロン酸などが
検討されている。中でも、ヒアルロン酸は本来、ヒトの
体内に存在する物質であり、さらに眼科手術補助剤や関
節注入剤などの医薬品として長い使用実績があることか
ら、その生体適合性と生体吸収性は充分に確認されてい
た。しかし、ヒアルロン酸は水溶性である為、それ自体
では培養基材としての利用には制限があった。[0003] As a material for a culture substrate used for such artificial skin, it is desirable to use a material that can be selected from various forms according to damage in addition to high biocompatibility and bioabsorbability.
Collagen, chondroitin sulfate, hyaluronic acid and the like have been studied. Above all, hyaluronic acid is a substance originally present in the human body and has a long track record of use as an ophthalmic surgery adjuvant and a drug for joint injection, so its biocompatibility and bioabsorbability have been fully confirmed. It had been. However, since hyaluronic acid is water-soluble, its use as a culture substrate by itself has been limited.
【0004】そこで、他の材料と組み合わせる、あるい
は、ヒアルロン酸を化学的に修飾して難水溶性とする試
みがなされてきた。例えば、(1)ヒアルロン酸とアミ
ノ基あるいはイミノ基を有する高分子化合物とのイオン
複合体からなる水不溶性の医療材料(特開平6−731
03号)、(2)ヒアルロン酸と架橋剤ジ(もしくは
ビ)ヒドラジン又はジ(もしくはビ)ヒドラジドとの縮
合反応による水不溶性の生体適合性材料(特開平9−5
9303号)、(3)ヒアルロン酸と脂肪族、芳香脂肪
族、などとの完全または部分エステルからなる外科皮膚
科用人工皮膚(特許2569012号)、等がある。Therefore, attempts have been made to combine with other materials or to chemically modify hyaluronic acid to make it hardly water-soluble. For example, (1) a water-insoluble medical material comprising an ionic complex of hyaluronic acid and a polymer compound having an amino group or an imino group (JP-A-6-731)
No. 03), (2) a water-insoluble biocompatible material by a condensation reaction between hyaluronic acid and a crosslinking agent di (or bi) hydrazine or di (or bi) hydrazide (Japanese Patent Laid-Open No. 9-5)
No. 9303), and (3) artificial skin for surgical dermatology comprising a complete or partial ester of hyaluronic acid and an aliphatic or araliphatic ester (Japanese Patent No. 2569012).
【0005】しかし、(1)はヒアルロン酸それ自体で
は担体を形成しておらず、又、(2)と(3)は化学構
造が本来のヒアルロン酸とは異なる物質となっている。However, (1) does not form a carrier by itself, and (2) and (3) are substances whose chemical structures are different from those of the original hyaluronic acid.
【0006】[0006]
【発明が解決しようとする課題】ヒアルロン酸自体が本
来持っている優れた生体適合性の特長を最大限生かすた
めに、何ら化学的架橋剤や化学修飾剤を使用することな
く、またカチオン性の高分子化合物と複合体を形成する
ことなくヒアルロン酸そのものを難水溶性にする手段は
これまで開発されていなかった。我々は、架橋剤等を使
用しないでヒアルロン酸単独からなる難水溶性ヒアルロ
ン酸ゲルを簡便な方法で製造することを初めて見出し
(PCT/JP98/03536号)、今回、この難水
溶性ヒアルロン酸ゲルの細胞培養基材への適用の可能性
を鋭意検討し、その有用性を見出し本発明を完成するに
至った。SUMMARY OF THE INVENTION In order to make the most of the inherent biocompatibility inherent in hyaluronic acid itself, it is necessary to use no chemical cross-linking agent or chemical modifier and to use a cationic A means for rendering hyaluronic acid itself poorly water-soluble without forming a complex with a polymer compound has not been developed so far. We have found for the first time to produce a poorly water-soluble hyaluronic acid gel composed of hyaluronic acid alone without using a crosslinking agent or the like by a simple method (PCT / JP98 / 03536). The present inventors have intensively studied the possibility of application of the present invention to a cell culture substrate, found its usefulness, and completed the present invention.
【0007】[0007]
【課題を解決するための手段】即ち、本発明は、(1)
中性水溶液に難溶性であるヒアルロン酸単独で形成され
たゲルを含有する細胞培養用基材、(2)次の(a)、
(b)の要件を満たすヒアルロン酸単独で形成されたゲ
ルを含有することを特徴とする細胞培養用基材、(a)
中性の37℃の水溶液で12時間での溶解率が50%以
下である、(b)ヒアルロン酸の促進酸加水分解条件下
でヒアルロン酸ゲルを処理することで可溶化されたヒア
ルロン酸が分岐構造を有し、該可溶化されたヒアルロン
酸中に、分岐度が0.5以上の分子量フラクションを部
分的に含む、(3)ヒアルロン酸単独で形成されたゲル
が、シート状、フィルム状、破砕状、スポンジ状、塊
状、繊維状、又はチューブ状からなる群より選択した1
種であることを特徴とする(2)記載の細胞培養用基
材、(4)中性の37℃の水溶液で12時間での溶解率
が50%以下であり、ヒアルロン酸の促進酸加水分解条
件下でヒアルロン酸ゲルを処理することで可溶化された
ヒアルロン酸中に、分岐度が0.5以上の分子量フラク
ションを部分的に含むヒアルロン酸ゲルと、ゲル化され
ていないヒアルロン酸を含む細胞培養用基材、(5)シ
ート状、フィルム状、破砕状、スポンジ状、塊状、繊維
状、又はチューブ状であるヒアルロン酸単独で形成され
たヒアルロン酸ゲルと、ゲル化されていないヒアルロン
酸を含む細胞培養用基材、(6)細胞培養用基材が人工
皮膚用である(1)〜(5)のいずれか1項に記載の細
胞培養用基材である。That is, the present invention provides (1)
A cell culture substrate containing a gel formed of hyaluronic acid alone which is hardly soluble in a neutral aqueous solution, (2) the following (a),
(A) a cell culture substrate comprising a gel formed of hyaluronic acid alone which satisfies the requirement of (b);
(B) Hyaluronic acid solubilized by treating a hyaluronic acid gel under conditions of accelerated acid hydrolysis of hyaluronic acid is 50% or less in a neutral aqueous solution at 37 ° C. in 12 hours. (3) a gel formed solely of hyaluronic acid, which has a structure and partially contains a molecular weight fraction having a degree of branching of 0.5 or more in the solubilized hyaluronic acid, 1 selected from the group consisting of crushed, sponge, lump, fibrous, or tubular
(2) the cell culture substrate according to (2), which has a dissolution rate of 50% or less in 12 hours in a neutral aqueous solution at 37 ° C., and promotes acid hydrolysis of hyaluronic acid; Hyaluronic acid gel partially containing a molecular weight fraction having a degree of branching of 0.5 or more in hyaluronic acid solubilized by treating the hyaluronic acid gel under conditions, and cells containing hyaluronic acid that has not been gelated A culture substrate, (5) a sheet-shaped, film-shaped, crushed, sponge-shaped, lump-shaped, fibrous, or tube-shaped hyaluronic acid gel formed of hyaluronic acid alone, and a non-gelled hyaluronic acid. (6) The cell culture substrate according to any one of (1) to (5), wherein the cell culture substrate is for artificial skin.
【0008】[0008]
【発明の実施の形態】以下、本発明を詳細に説明する。
本発明でいうヒアルロン酸ゲルとは、三次元網目構造を
もつ高分子及びその膨潤体である。三次元網目構造はヒ
アルロン酸の架橋構造によって形成されている。BEST MODE FOR CARRYING OUT THE INVENTION Hereinafter, the present invention will be described in detail.
The hyaluronic acid gel referred to in the present invention is a polymer having a three-dimensional network structure and a swollen body thereof. The three-dimensional network structure is formed by a cross-linked structure of hyaluronic acid.
【0009】その一例としては、ヒアルロン酸のpH
3.5以下の水溶液を凍結し、次いで解凍することでシ
ート状、フィルム状、破砕状、スポンジ状、塊状、繊維
状、又はチューブ状の中性水溶液に難溶性であるヒアル
ロン酸ゲルを得ることができる。より具体的には以下に
述べる。One example is the pH of hyaluronic acid.
Freezing and then thawing an aqueous solution of 3.5 or less to obtain a hyaluronic acid gel which is hardly soluble in a neutral aqueous solution in a sheet, film, crushed, sponge, lump, fibrous, or tubular form. Can be. This will be described more specifically below.
【0010】本発明に用いられるヒアルロン酸は、動物
組織から抽出したものでも、また発酵法で製造したもの
でもその起源を問うことなく使用できる。発酵法で使用
する菌株は自然界から分離されるストレプトコッカス属
等のヒアルロン酸生産能を有する微生物、又は特開昭6
3−123392号公報に記載したストレプトコッカス
・エクイFM−100(微工研菌寄第9027号) 、特開平
2−234689号公報に記載したストレプトコッカス
・エクイFM−300(微工研菌寄第2319号) のような
高収率で安定にヒアルロン酸を生産する変異株が望まし
い。上記の変異株を用いて培養、精製されたものが用い
られる。The hyaluronic acid used in the present invention can be used regardless of its origin, whether it is extracted from animal tissues or manufactured by fermentation. The strain used in the fermentation method is a microorganism having hyaluronic acid-producing ability, such as Streptococcus sp.
No. 3-123392, Streptococcus equi FM-100 (Microtechnical Laboratories No. 9027), and Streptococcus equi FM-300 described in Japanese Patent Application Laid-Open No. Hei 2-234689 (Microtechnical Labs No. 2319) )), A mutant which stably produces hyaluronic acid in high yield is desirable. Those cultured and purified using the above mutant strains are used.
【0011】本発明に用いられるヒアルロン酸の分子量
は、約1×105 〜約1×107 ダルトンの範囲内のも
のが好ましい。また、上記範囲内の分子量をもつもので
あれば、より高分子量のものから、加水分解処理等をし
て得たものでも同様に好ましく使用できる。なお、本発
明にいうヒアルロン酸は、そのアルカリ金属塩、例え
ば、ナトリウム、カリウム、リチウムの塩をも包含する
概念で使用される。The molecular weight of the hyaluronic acid used in the present invention is preferably in the range of about 1 × 10 5 to about 1 × 10 7 daltons. In addition, as long as it has a molecular weight within the above range, those obtained by subjecting them to hydrolysis treatment or the like from those having a higher molecular weight can also be preferably used. It should be noted that the hyaluronic acid according to the present invention is used in a concept that also includes alkali metal salts thereof, for example, sodium, potassium and lithium salts.
【0012】本発明でいうヒアルロン酸単独とは、ヒア
ルロン酸以外に化学的架橋剤や化学的修飾剤等は使用し
ないことまた、カチオン性の高分子と複合体化しないこ
とであり、自己架橋を意味するものである。[0012] The term "hyaluronic acid alone" as used in the present invention means that no chemical crosslinking agent or chemical modifier other than hyaluronic acid is used, and that it does not form a complex with a cationic polymer. Is what it means.
【0013】本発明でいうヒアルロン酸ゲルは、ヒアル
ロン酸の促進酸加水分解反応条件下でヒアルロン酸ゲル
を処理することで分解、可溶化することができる。可溶
化されたヒアルロン酸が架橋構造を保持している場合、
分岐点を有するヒアルロン酸として高分子溶液論的に直
鎖状のヒアルロン酸と区別することができる。The hyaluronic acid gel referred to in the present invention can be decomposed and solubilized by treating the hyaluronic acid gel under the conditions of the accelerated acid hydrolysis reaction of hyaluronic acid. When the solubilized hyaluronic acid retains a crosslinked structure,
Hyaluronic acid having a branch point can be distinguished from linear hyaluronic acid in terms of polymer solution theory.
【0014】本発明でいうヒアルロン酸の促進酸加水分
解反応条件としては、水溶液のpH1.5、温度60℃
が適当である。ヒアルロン酸のグリコシド結合の加水分
解による主鎖切断反応が、中性の水溶液中と比較して、
酸性やアルカリ性の水溶液中で著しく促進される。更に
酸加水分解反応は、反応温度が高い方が促進される。The conditions for the accelerated acid hydrolysis reaction of hyaluronic acid referred to in the present invention include a pH of an aqueous solution of 1.5 and a temperature of 60 ° C.
Is appropriate. The main chain cleavage reaction due to hydrolysis of the glycosidic bond of hyaluronic acid, compared with neutral aqueous solution,
Significantly promoted in acidic or alkaline aqueous solutions. Further, the acid hydrolysis reaction is promoted at a higher reaction temperature.
【0015】本発明ではGPC−MALLS法を用い、
GPCで分離された分子量フラクションの分子量と分岐
度をオンラインで連続的に測定した。本発明では、同一
溶出体積のフラクションの可溶化されたヒアルロン酸の
分子量と対照となる直鎖状ヒアルロン酸の分子量を比較
して分岐度を計算する溶出体積法を使って分岐度の測定
を行った。分岐度は可溶化されたヒアルロン酸の高分子
鎖1コ当たりに存在する分岐点の数であり、可溶化され
たヒアルロン酸の分子量に対してプロットされる。In the present invention, the GPC-MALLS method is used,
The molecular weight and the degree of branching of the molecular weight fraction separated by GPC were continuously measured online. In the present invention, the degree of branching is measured by using the elution volume method of calculating the degree of branching by comparing the molecular weight of the solubilized hyaluronic acid of the fraction having the same elution volume with the molecular weight of the linear hyaluronic acid as a control. Was. The degree of branching is the number of branch points present per one polymer chain of solubilized hyaluronic acid, and is plotted against the molecular weight of solubilized hyaluronic acid.
【0016】可溶化されたヒアルロン酸は、GPC溶媒
で希釈して濃度を調製し、0.2μmのメンブランフィ
ルターでろ過した後測定に供した。本発明でいうヒアル
ロン酸ゲル中に、ヒアルロン酸の促進酸加水分解条件下
でも安定に存在する架橋構造がある場合、可溶化された
ヒアルロン酸に分岐構造が高分子溶液論的に確認され
る。本発明でいうヒアルロン酸ゲルの分岐度は、0.5
以上である。The solubilized hyaluronic acid was diluted with a GPC solvent to adjust the concentration, filtered through a 0.2 μm membrane filter, and used for measurement. In the case where the hyaluronic acid gel referred to in the present invention has a cross-linked structure that is stably present even under the accelerated acid hydrolysis conditions of hyaluronic acid, a branched structure is confirmed in the solubilized hyaluronic acid in terms of a polymer solution. The degree of branching of the hyaluronic acid gel referred to in the present invention is 0.5
That is all.
【0017】ヒアルロン酸の水溶液のpHを調整するた
めに使用する酸は、pH3.5以下に調整できる酸であ
れば、いずれの酸も使用することができる。酸の使用量
を低減するために、好ましくは強酸、例えば、塩酸、硝
酸、硫酸等を使用することが望ましい。As the acid used for adjusting the pH of the aqueous solution of hyaluronic acid, any acid can be used as long as the pH can be adjusted to 3.5 or less. In order to reduce the amount of acid used, it is desirable to use a strong acid, for example, hydrochloric acid, nitric acid, sulfuric acid and the like.
【0018】ヒアルロン酸の水溶液のpHは、ヒアルロ
ン酸のカルボキシル基が充分な割合でプロトン化するp
Hに調整する。調整されるpHはヒアルロン酸塩の対イ
オンの種類、ヒアルロン酸の分子量、水溶液濃度、凍結
及び解凍の条件、並びに生成するゲルの強さ等の諸特性
により適宜決められるが、本発明では、pH3.5以
下、好ましくは、pH2.5以下に調整することであ
る。The pH of the aqueous solution of hyaluronic acid is such that the carboxyl groups of hyaluronic acid are protonated at a sufficient rate.
Adjust to H. The pH to be adjusted is appropriately determined according to various kinds of properties such as the type of the counter ion of the hyaluronic acid salt, the molecular weight of the hyaluronic acid, the concentration of the aqueous solution, the conditions for freezing and thawing, and the strength of the gel to be formed. The pH is adjusted to 0.5 or less, preferably to 2.5 or less.
【0019】凍結、解凍はヒアルロン酸の調整された酸
性水溶液を、任意の容器に入れた後、所定の温度で凍結
させ、凍結が終わった後、所定の温度で解凍させる操作
を少なくとも1回行う。凍結、解凍の温度と時間は、容
器の大きさ、水溶液量によりヒアルロン酸の酸性水溶液
が凍結、解凍する温度と時間の範囲内で適宜決められる
が、一般には、氷点以下の凍結温度、氷点以上の解凍温
度が好ましい。凍結、解凍時間を短くできることから、
更に好ましくは−5℃以下の凍結温度、5℃以上の解凍
温度が選ばれる。また、時間は、その温度で凍結、解凍
が終了する時間以上であれば特に制限されない。For freezing and thawing, an operation of placing an acidic aqueous solution of hyaluronic acid in an arbitrary container, freezing it at a predetermined temperature, and thawing at a predetermined temperature after freezing is performed at least once. . The temperature and time for freezing and thawing are appropriately determined within the range of the temperature and time for freezing and thawing the acidic aqueous solution of hyaluronic acid depending on the size of the container and the amount of the aqueous solution. Is preferred. Freezing and thawing time can be shortened,
More preferably, a freezing temperature of −5 ° C. or less and a thawing temperature of 5 ° C. or more are selected. The time is not particularly limited as long as it is equal to or longer than the time at which freezing and thawing is completed at that temperature.
【0020】ヒアルロン酸の調整された酸性水溶液を凍
結し、次いで解凍する操作の繰り返し回数は、使用する
ヒアルロン酸の分子量、水溶液濃度、水溶液のpH、凍
結及び解凍の温度と時間、並びに生成するゲルの強さ等
の諸特性により適宜決められる。通常は1回以上繰り返
すことが好ましい。また、凍結、解凍の操作を繰り返す
ごとに、その凍結、解凍の温度及び時間を変えても構わ
ない。The number of repetitions of the operation of freezing and then thawing the adjusted acidic aqueous solution of hyaluronic acid depends on the molecular weight of the hyaluronic acid used, the concentration of the aqueous solution, the pH of the aqueous solution, the temperature and time of freezing and thawing, and the gel formed. It is appropriately determined according to various characteristics such as the strength of the rubber. Normally, it is preferable to repeat it one or more times. Further, each time the operation of freezing and thawing is repeated, the temperature and time of freezing and thawing may be changed.
【0021】ヒアルロン酸の調整された酸性溶液の凍結
解凍により得られたヒアルロン酸ゲルは、ヒアルロン酸
の酸加水分解を避けるために、酸性に調整するために用
いた酸等の成分を除く必要がある。酸等の成分を除くた
めには、通常は水性溶媒による洗浄か透析をする。使用
する溶媒は、ヒアルロン酸ゲルの機能を損なわないもの
であれば特に制限はないが、例えば、水、生理食塩水、
リン酸緩衝液等が用いられるが、好ましくは、生理食塩
水、リン酸緩衝液等が用いられる。The hyaluronic acid gel obtained by freezing and thawing the adjusted acidic solution of hyaluronic acid needs to exclude components such as acids used for adjusting the acidity in order to avoid acid hydrolysis of hyaluronic acid. is there. In order to remove components such as acids, washing or dialysis is usually performed with an aqueous solvent. The solvent to be used is not particularly limited as long as it does not impair the function of the hyaluronic acid gel, for example, water, saline,
Phosphate buffer and the like are used, and preferably, physiological saline, phosphate buffer and the like are used.
【0022】また、洗浄・透析方法は、特に制限はない
が、通常は、バッチ法、濾過法、カラム等に充填して通
液する方法等が、また、透析の場合、透析膜、限外ろ過
膜による方法等が好適に用いられる。これらの条件は、
液量、回数等を含めて、除きたい成分を目標の濃度以下
にできる条件であればよく、ヒアルロン酸ゲルの形態や
用途により適宜選択することが可能である。The washing / dialysis method is not particularly limited, but is usually a batch method, a filtration method, a method of filling a column or the like, and passing the solution through. A method using a filtration membrane or the like is suitably used. These conditions are:
Any conditions can be used as long as the components to be removed, including the amount of liquid and the number of times, can be reduced to the target concentration or less, and can be appropriately selected depending on the form and use of the hyaluronic acid gel.
【0023】この洗浄・透析されたヒアルロン酸ゲル
は、その使用目的に応じて、溶媒中に浸漬した状態、溶
媒を含ませた湿潤状態、風乾、減圧乾燥あるいは凍結乾
燥等の処理を経た乾燥状態で細胞培養用基材として供さ
れる。The washed and dialyzed hyaluronic acid gel may be immersed in a solvent, wet with a solvent, air-dried, dried under reduced pressure or freeze-dried depending on the purpose of use. To serve as a substrate for cell culture.
【0024】ヒアルロン酸ゲルの成形加工等の処理は、
作製時には、ヒアルロン酸の調整された酸性溶液の凍結
時の容器や手法の選択によりシート状、フィルム状、破
砕状、スポンジ状、繊維状、又チューブ状の所望の形態
のヒアルロン酸ゲルの作製が可能である。例えば、板上
にキャスティングして凍結することによりフィルム状及
びシート状の形態が得られるし、水と混和しない有機溶
剤と激しく混合撹拌しながら凍結解凍することにより破
砕状の形態が得られる。Processing such as molding of hyaluronic acid gel is as follows:
At the time of preparation, the desired form of sheet, film, crushed, sponge, fiber, or tube-shaped hyaluronic acid gel can be prepared by selecting the container and method for freezing the adjusted acidic solution of hyaluronic acid. It is possible. For example, a film-like or sheet-like form can be obtained by casting and freezing on a plate, or a crushed form can be obtained by freeze-thawing with vigorous mixing and stirring with an organic solvent immiscible with water.
【0025】ヒアルロン酸の分子量、濃度、などの条件
を変えることで、生体吸収性の異なる種々の難水溶性ヒ
アルロン酸ゲルが得られる。By changing the conditions such as the molecular weight and concentration of hyaluronic acid, various poorly water-soluble hyaluronic acid gels having different bioabsorbability can be obtained.
【0026】本発明の難水溶性ヒアルロン酸ゲルを含有
する細胞培養用基材は、それ自体で、あるいは他の生理
活性物質、生体適合性物質、抗生物質等と組合わせて利
用できる。The substrate for cell culture containing the poorly water-soluble hyaluronic acid gel of the present invention can be used by itself or in combination with other physiologically active substances, biocompatible substances, antibiotics and the like.
【0027】生理活性物質としては、培養する細胞の成
長を促進する因子が重要であり、例えば、インシュリ
ン、肝細胞成長因子、トンラスフォーミング成長因子、
神経成長因子、上皮成長因子、血小板由来成長因子、イ
ンシュリン様成長因子、線維芽細胞成長因子、コロニー
刺激因子、エリスロポイエチン、トランスフェリン、イ
ンターロイキン、インターフェロン等が挙げられる。As the physiologically active substance, factors that promote the growth of cells to be cultured are important. Examples of such factors include insulin, hepatocyte growth factor, torus forming growth factor, and the like.
Examples include nerve growth factor, epidermal growth factor, platelet-derived growth factor, insulin-like growth factor, fibroblast growth factor, colony stimulating factor, erythropoietin, transferrin, interleukin, interferon and the like.
【0028】生体適合性物質としては、培養する細胞の
接着を促進する物質が重要であり、例えば、コラーゲ
ン、フィブロネクチン、ビトロネクチン、ラミニン、ア
ルブミン、コンドロイチン硫酸、ケラタン硫酸、へパラ
ン硫酸、ヒアルロン酸等が挙げられる。As the biocompatible substance, a substance that promotes adhesion of cells to be cultured is important, and examples thereof include collagen, fibronectin, vitronectin, laminin, albumin, chondroitin sulfate, keratan sulfate, heparan sulfate, and hyaluronic acid. No.
【0029】抗生物質としては、ストレプトマイシン、
ペニシリン、トブラマイシン、アミカシン、ゲンタマイ
シン、ネオマイシン、アンホテリシンB等が挙げられ
る。As antibiotics, streptomycin,
Penicillin, tobramycin, amikacin, gentamicin, neomycin, amphotericin B and the like.
【0030】本発明の難水溶性ヒアルロン酸ゲルを含有
する細胞培養用基材は、各種細胞をその内部及び又は表
面で培養することができ、人工皮膚などの人工臓器の構
築材料として利用できる他、細胞培養による有用物質の
生産にも利用できる。The substrate for cell culture containing the poorly water-soluble hyaluronic acid gel of the present invention allows various cells to be cultured inside and / or on its surface, and can be used as a material for constructing artificial organs such as artificial skin. It can also be used for producing useful substances by cell culture.
【0031】本発明の細胞培養用基材に自家皮膚細胞を
培養し、熱傷、擦過傷、潰瘍等による皮膚創傷の治療に
おいて、自家移植物として用いることができる。同様に
自家粘膜細胞を培養し、口腔内等の粘膜の損傷の治療に
用いることができる。Autologous skin cells can be cultured on the cell culture substrate of the present invention and used as an autograft in the treatment of skin wounds caused by burns, abrasions, ulcers and the like. Similarly, autologous mucosal cells can be cultured and used for treatment of damage to mucous membranes in the oral cavity and the like.
【0032】[0032]
【実施例】以下、本発明を実施例により具体的に示す
が、本発明はこれらの実施例に限定されるものではな
い。EXAMPLES Hereinafter, the present invention will be described specifically with reference to Examples, but the present invention is not limited to these Examples.
【0033】調製例1:シート状の難水溶性ヒアルロン
酸ゲルの作製 分子量2×106 ダルトンのヒアルロン酸を蒸留水に溶
解し、1%の溶液を調製した。この水溶液に1N硝酸を
添加しpH1.5に調整した後、この溶液を平底の容器
に入れ、−20℃に設定した冷凍庫で凍結した。5日後
に取り出し25℃で解凍し難水溶性ヒアルロン酸ゲルを
得た。次に、このゲルをpH7の25mMリン酸緩衝生
理食塩水100mlに24時間浸漬中和した後、蒸留水
で十分にろ過洗浄し、乾燥してシート状の難水溶性ヒア
ルロン酸ゲルを得た。Preparation Example 1: Preparation of a sheet-shaped poorly water-soluble hyaluronic acid gel Hyaluronic acid having a molecular weight of 2 × 10 6 daltons was dissolved in distilled water to prepare a 1% solution. After adjusting the pH to 1.5 by adding 1N nitric acid to the aqueous solution, the solution was placed in a flat-bottomed container and frozen in a freezer set at -20 ° C. After 5 days, it was taken out and thawed at 25 ° C to obtain a poorly water-soluble hyaluronic acid gel. Next, the gel was immersed and neutralized in 100 ml of 25 mM phosphate buffered saline having a pH of 7 for 24 hours, then sufficiently filtered and washed with distilled water, and dried to obtain a sheet-like poorly water-soluble hyaluronic acid gel.
【0034】実施例1:難水溶性ヒアルロン酸ゲルの溶
解性試験 生理食塩水に50mM濃度でリン酸緩衝成分を加え、p
H7のリン酸緩衝生理食塩水を調製した。調製例1で作
製した難水溶性ヒアルロン酸ゲルを50mlのリン酸緩
衝生理食塩水に浸漬し緩やかに攪拌した。37℃でリン
酸緩衝生理食塩水中に溶出するヒアルロン酸の割合を、
リン酸緩衝生理食塩水中のヒアルロン酸濃度から求め
た。Example 1: Solubility test of poorly water-soluble hyaluronic acid gel A phosphate buffer component was added to physiological saline at a concentration of 50 mM, and p
H7 phosphate buffered saline was prepared. The poorly water-soluble hyaluronic acid gel prepared in Preparation Example 1 was immersed in 50 ml of phosphate buffered saline and gently stirred. The percentage of hyaluronic acid eluted in phosphate buffered saline at 37 ° C.
It was determined from the concentration of hyaluronic acid in phosphate buffered saline.
【0035】ヒアルロン酸濃度の測定 リン酸緩衝生理食塩水中のヒアルロン酸濃度は、GPC
を使って、示差屈折率検出器のピーク面積から求めた。Measurement of Hyaluronic Acid Concentration Hyaluronic acid concentration in phosphate buffered saline was measured by GPC
Was determined from the peak area of the differential refractive index detector.
【0036】その結果、調製例1で得られたヒアルロン
酸ゲルの溶解率は、12時間経過後では、2%であり、
24時間経過後では、4%であり、24時間経過しても
86%のヒアルロン酸ゲルが残存していた。よって、調
製例1で得られたヒアルロン酸ゲルは、中性水溶液に難
溶性であることが示唆される。As a result, the dissolution rate of the hyaluronic acid gel obtained in Preparation Example 1 was 2% after 12 hours,
It was 4% after 24 hours, and 86% of the hyaluronic acid gel remained after 24 hours. Therefore, it is suggested that the hyaluronic acid gel obtained in Preparation Example 1 is poorly soluble in a neutral aqueous solution.
【0037】実施例2:難水溶性ヒアルロン酸ゲルの分
岐度測定 調製例1で得られた難水溶性ヒアルロン酸ゲルを、pH
1.5の塩酸水溶液15mlに浸漬し、60℃、6時間
の加水分解を行った。ゲルは加水分解により可溶化さ
れ、これをGPC溶媒で2倍に希釈して濃度を0.05
重量%に調製し、0.2μmのメンブレンフィルターで
濾過した後、0.1ml注入してGPC−MALLSの
測定を行った結果、分岐度0.5以上であった。Example 2: Measurement of degree of branching of poorly water-soluble hyaluronic acid gel The poorly water-soluble hyaluronic acid gel obtained in Preparation Example 1 was subjected to pH
It was immersed in 15 ml of 1.5 aqueous hydrochloric acid solution and hydrolyzed at 60 ° C. for 6 hours. The gel was solubilized by hydrolysis, and diluted twice with GPC solvent to a concentration of 0.05.
% By weight, filtered through a 0.2 μm membrane filter, injected 0.1 ml, and measured for GPC-MALLS. As a result, the degree of branching was 0.5 or more.
【0038】実施例3:生体吸収性試験 マウス(ICR♀8週令)の腹腔内に開腹手術により調
製例1の難水溶性ヒアルロン酸ゲルあるいは1ml1%
ヒアルロン酸溶液を入れた。術後2、4、8日後に開腹
し、残存するゲルを回収し、腹腔内に生理食塩水2ml
を注入し、よく撹拌し液を回収した。このゲルと液をア
ルカリ処理(0.1NNaOH、2h)した後、中和
し、ゲルろ過(ShodexOHpakKB806)に
よりヒアルロン酸濃度を測定し残存率を算出した。その
結果を表1に示す。Example 3 Bioabsorbability Test The poorly water-soluble hyaluronic acid gel of Preparation Example 1 or 1 ml 1% intraperitoneally intraperitoneally of a mouse (ICR @ 8 weeks old)
The hyaluronic acid solution was charged. After 2, 4 and 8 days after the operation, the abdomen was opened, the remaining gel was collected, and 2 ml of physiological saline was intraperitoneally injected.
And the mixture was stirred well to collect the liquid. The gel and the solution were alkali-treated (0.1 N NaOH, 2 h), neutralized, and the concentration of hyaluronic acid was measured by gel filtration (ShodexOHpakKB806) to calculate the residual ratio. Table 1 shows the results.
【0039】[0039]
【表1】 [Table 1]
【0040】表1より、調製例1で得られたヒアルロン
酸ゲルは、4日後で41%残存していたのに対してヒア
ルロン酸溶液は0%であり、本発明のヒアルロン酸ゲル
は、生体内滞留時間が長いことが示唆される。即ち、ヒ
アルロン酸溶液と比較して、生体内での吸収速度が遅
く、生体吸収性の、細胞培養用基材として有用な性質を
有していることが示唆される。According to Table 1, the hyaluronic acid gel obtained in Preparation Example 1 had 41% remaining after 4 days, whereas the hyaluronic acid solution was 0%. It suggests a long residence time in the body. That is, compared with the hyaluronic acid solution, the absorption rate in the living body is slow, suggesting that it has a bioabsorbable property useful as a cell culture substrate.
【0041】実施例4:細胞培養試験 35mmの細胞培養用シャーレに、調製例1で作製した
シート状の難水溶性ヒアルロン酸ゲル(2×2cm)、
調製例1と同量のヒアルロン酸を凍結乾燥したシート
(2×2cm)、を入れて、2×104 個の正常ヒト新
生児包皮由来線維芽細胞を10%FCS−DMEM培地
中、37℃のCO2 インキュベータで培養し、シャーレ
単独の場合と比較した。3日後と5日後、トリプシン/
EDTAにより細胞を回収し、細胞を計数した。その結
果を表2に示す。Example 4: Cell culture test A sheet-like poorly water-soluble hyaluronic acid gel (2 × 2 cm) prepared in Preparation Example 1 was placed in a 35 mm cell culture dish.
A sheet (2 × 2 cm) obtained by freeze-drying the same amount of hyaluronic acid as in Preparation Example 1 was placed, and 2 × 10 4 normal human neonatal foreskin-derived fibroblasts were placed at 37 ° C. in 10% FCS-DMEM medium. The cells were cultured in a CO 2 incubator and compared with the case of a petri dish alone. After 3 and 5 days, trypsin /
The cells were collected by EDTA, and the cells were counted. Table 2 shows the results.
【0042】[0042]
【表2】 [Table 2]
【0043】その結果、倒立型位相差顕微鏡で観察した
ところ、シャーレ単独ではシャーレ上に細胞が付着して
おり、難水溶性ヒアルロン酸ゲルの場合は、シートの上
及び内部に細胞が観察されたが、ヒアルロン酸を凍結乾
燥したものは、シートは溶解し原形を留めず細胞はシャ
ーレ上にあった。これらの細胞数は表2に示すように、
増殖性には大きな違いは認められず、シート状の難水溶
性ヒアルロン酸ゲルに皮膚細胞を培養したものは、人工
皮膚として好適である。As a result, when observed with an inverted phase-contrast microscope, cells adhered to the petri dish alone, and in the case of poorly water-soluble hyaluronic acid gel, cells were observed on and inside the sheet. However, when the hyaluronic acid was freeze-dried, the sheet was dissolved, the original shape was not retained, and the cells were on the petri dish. These cell numbers are shown in Table 2,
There is no significant difference in the proliferative property, and the one obtained by culturing skin cells on a sheet-like poorly water-soluble hyaluronic acid gel is suitable as artificial skin.
【0044】[0044]
【発明の効果】本発明により、ヒアルロン酸単独で形成
された難水溶性のヒアルロン酸ゲルを含有する細胞培養
用基材を提供することができる。かかる本発明の細胞培
養用基材は、架橋剤等を使用していないため、安全性及
び生体適合性に優れ、各種細胞を培養用基材の内部及び
又は表面で培養することにより、人工皮膚等の人工臓器
の構築材料として利用できる他、細胞培養による有用物
質の生産にも利用できる等の効果を奏する。According to the present invention, it is possible to provide a cell culture substrate containing a poorly water-soluble hyaluronic acid gel formed of hyaluronic acid alone. Since such a cell culture substrate of the present invention does not use a crosslinking agent or the like, it is excellent in safety and biocompatibility, and by culturing various cells inside and / or on the culture substrate, artificial skin In addition to being usable as a material for constructing an artificial organ such as the above, the present invention has an effect that it can be used for producing a useful substance by cell culture.
Claims (6)
単独で形成されたゲルを含有する細胞培養用基材。1. A cell culture substrate comprising a gel formed of hyaluronic acid alone, which is hardly soluble in a neutral aqueous solution.
ルロン酸単独で形成されたゲルを含有することを特徴と
する細胞培養用基材。(a)中性の37℃の水溶液で1
2時間での溶解率が50%以下である、(b)ヒアルロ
ン酸の促進酸加水分解条件下でヒアルロン酸ゲルを処理
することで可溶化されたヒアルロン酸が分岐構造を有
し、該可溶化されたヒアルロン酸中に、分岐度が0.5
以上の分子量フラクションを部分的に含む。2. A cell culture substrate comprising a gel formed of hyaluronic acid alone, which satisfies the following requirements (a) and (b). (A) 1 with a neutral 37 ° C. aqueous solution
(B) hyaluronic acid solubilized by treating the hyaluronic acid gel under accelerated acid hydrolysis conditions for hyaluronic acid having a dissolution rate of 50% or less in 2 hours has a branched structure; In the hyaluronic acid thus obtained, the degree of branching is 0.5
The above molecular weight fraction is partially contained.
シート状、フィルム状、破砕状、スポンジ状、塊状、繊
維状、又はチューブ状からなる群より選択した1種であ
ることを特徴とする請求項2記載の細胞培養用基材。3. A gel formed with hyaluronic acid alone,
3. The cell culture substrate according to claim 2, wherein the substrate is one selected from the group consisting of a sheet, a film, a crushed, a sponge, a lump, a fiber, and a tube.
解率が50%以下であり、ヒアルロン酸の促進酸加水分
解条件下でヒアルロン酸ゲルを処理することで可溶化さ
れたヒアルロン酸中に、分岐度が0.5以上の分子量フ
ラクションを部分的に含むヒアルロン酸ゲルと、ゲル化
されていないヒアルロン酸を含む細胞培養用基材。4. A hyaluronic acid which has a solubility of 50% or less in 12 hours in a neutral aqueous solution at 37 ° C. and is solubilized by treating a hyaluronic acid gel under conditions of accelerated acid hydrolysis of hyaluronic acid. A cell culture substrate comprising a hyaluronic acid gel partially containing a molecular weight fraction having a degree of branching of 0.5 or more and a non-gelled hyaluronic acid.
ジ状、塊状、繊維状、又はチューブ状であるヒアルロン
酸単独で形成されたヒアルロン酸ゲルと、ゲル化されて
いないヒアルロン酸を含む細胞培養用基材。5. A cell culture containing a hyaluronic acid gel formed of hyaluronic acid alone in a sheet, film, crushed, sponge, massive, fibrous, or tubular form, and a non-gelled hyaluronic acid. Substrate.
項1〜5のいずれか1項に記載の細胞培養用基材。6. The cell culture substrate according to claim 1, wherein the cell culture substrate is for artificial skin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11043286A JP2000239304A (en) | 1999-02-22 | 1999-02-22 | Cell culture substrate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11043286A JP2000239304A (en) | 1999-02-22 | 1999-02-22 | Cell culture substrate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2000239304A true JP2000239304A (en) | 2000-09-05 |
Family
ID=12659571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP11043286A Withdrawn JP2000239304A (en) | 1999-02-22 | 1999-02-22 | Cell culture substrate |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2000239304A (en) |
-
1999
- 1999-02-22 JP JP11043286A patent/JP2000239304A/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cao et al. | Double crosslinked HLC-CCS hydrogel tissue engineering scaffold for skin wound healing | |
| EP1681306B1 (en) | Hyaluronic acid compound, hydrogel thereof and material for treating joint | |
| JP3359909B2 (en) | Hyaluronic acid gel, method for producing the same, and medical material containing the same | |
| US8178663B2 (en) | Ester derivatives of hyaluronic acid for the preparation of hydrogel materials by photocuring | |
| KR100730527B1 (en) | Hyaluronic acid gel composition, preparation method thereof and medical material containing same | |
| Kaparekar et al. | Fabrication and characterization of Chrysin–a plant polyphenol loaded alginate-chitosan composite for wound healing application | |
| CN106039416A (en) | Chitosan-sericin composite biological scaffold as well as preparation method and application thereof | |
| CN113350567A (en) | Biocompatible polymer dressing based on collagen | |
| CN118141976A (en) | Hydrogel compound and application thereof | |
| CN101134784B (en) | Agarose and hyaluronic acid graft and its preparation method and application | |
| Chen et al. | Preparation of enzymatically cross-linked sulfated chitosan hydrogel and its potential application in thick tissue engineering | |
| JP4959068B2 (en) | Cell tissue regeneration substrate | |
| WO2016085923A1 (en) | Process for preparing tissue regeneration matrix | |
| WO1996003147A1 (en) | Synthesis of chemical gels from polyelectrolyte polysaccharides by gamma-irradiation | |
| US20220160752A1 (en) | Genipin-crosslinked pdrn-sacran biopolymer scaffolds | |
| CN113350568A (en) | Biocompatible polymer dressing based on gelatin | |
| JPWO2003094985A1 (en) | Artificial extracellular matrix and method for producing the same | |
| JP2000239304A (en) | Cell culture substrate | |
| KR102546437B1 (en) | Powder type anti-adhesion agent comprising biocompatible polymer and method for manufacturing the same | |
| JP2003019194A (en) | Co-crosslinked gel composition comprising hyaluronic acid and carboxymethyl cellulose | |
| CN116966337B (en) | A degradable polymer repair material and preparation method thereof | |
| JP2020117540A (en) | Urethral stricture therapeutic agent and urethral stricture treatment method | |
| CN115054734B (en) | Plastic composite bone repair stent and preparation method thereof | |
| JP2000128789A (en) | Wound healing agent | |
| CA3077510A1 (en) | Urethral stricture treatment agent and urethral stricture treatment method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060113 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20090603 |